Clinical Trials Directory

Trials / Completed

CompletedNCT03496324

Ibuprofen 4% (w/v) Pivotal Bioequivalence Study

A Randomised, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic Study Comparing a 4% (w/v) Suspension of Ibuprofen With a Reference 2% (w/v) Suspension of Ibuprofen in the Fed and Fasted States.

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Reckitt Benckiser Healthcare (UK) Limited · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Bioequivalence evaluation of Nurofen for Children® with reference formulation of Algifor® Junior by determining and comparing the rate and extent of absorption in both fed and fasted states

Conditions

Interventions

TypeNameDescription
DRUGNurofen for Children®Nurofen for Children® 400 mg/10 ml
DRUGAlgifor® JuniorAlgifor® Junior 400 mg/20 ml

Timeline

Start date
2016-02-29
Primary completion
2016-05-06
Completion
2016-05-06
First posted
2018-04-12
Last updated
2019-06-05
Results posted
2019-06-05

Source: ClinicalTrials.gov record NCT03496324. Inclusion in this directory is not an endorsement.

Ibuprofen 4% (w/v) Pivotal Bioequivalence Study (NCT03496324) · Clinical Trials Directory